Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Nelfinavir Mesylate

Known as: Nelfinavir Monomethane Sulfonate, Sulfonate, Nelfinavir Monomethane, Mesylate, Nelfinavir 
The mesylate salt form of nelfinavir, a synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease… 
National Institutes of Health

Related topics

Related topics

17 relations

Narrower (2)

AG 1343Viracept
Acquired Immunodeficiency SyndromeAstemizoleCisaprideDrug Allergy
Expand

Broader (4)

Antiviral AgentsIsoquinolinesNelfinavirSulfonic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities
ABSTRACT Nelfinavir mesylate (Viracept, formally AG1343) is a potent and orally bioavailable human immunodeficiency virus (HIV… 
Highly Cited
1999
Highly Cited
1999
Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency… 
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Review
1999
Review
1999
Nelfinavir Mesylate: A Protease Inhibitor
OBJECTIVE: To review the clinical pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
1998
Highly Cited
1998
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.
A phase I/II dose-ranging open-label 28-day monotherapy study of the safety, pharmacokinetics, and antiviral activity of… 
Highly Cited
1998
Highly Cited
1998
Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir
ABSTRACT Nelfinavir mesylate (formerly AG1343) is a potent and selective inhibitor of human immunodeficiency virus (HIV) protease… 
Highly Cited
1998
Highly Cited
1998
Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
In vitro studies with human liver microsomes and P450 probe substrates were performed to characterize selectivity and mechanism… 
  • table 2
  • table 1
  • figure 1
  • table 3
  • table 4
Highly Cited
1997
Highly Cited
1997
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343… 
Review
1997
Review
1997
HIV-1 protease inhibitors. A review for clinicians.
OBJECTIVE The clinical care of people infected with human immunodeficiency virus (HIV) has been substantially affected by the… 
Highly Cited
1996
Highly Cited
1996
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
Dolasetron mesilate [(2 alpha, 6 alpha, 8 alpha, 9a beta)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-c arboxylate… 
Highly Cited
1988
Highly Cited
1988
21-Aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils.
U74006F (21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16 alpha-methylpregna-1,4,9(11)-triene-3,20-dione… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE